Immune low-response states significantly impact the effectiveness of immunotherapy in cancer treatment. These states typically arise from intricate molecular interactions between tumor cells and immune cells, which can suppress or alter the body's natural immune defense mechanisms. Recent breakthroughs in single-cell omics and spatial transcriptomics have equipped researchers with advanced tools to investigate these immune low-response environments with greater precision. Techniques such as ATAC-seq, TCR/BCR sequencing, RNA-seq, along with platforms like SLAT and STAligner, provide detailed insights into immune cell activity, gene expression profiles, and the dynamic nature of immune responses at the single-cell level. These technologies offer a deeper understanding of the mechanisms behind immunotherapy resistance and help clarify the role of immune cells in driving low-response states within cancer.
This Research Topic focuses on unraveling the molecular mechanisms that underpin immune low-response states, with an emphasis on the cellular and molecular interactions that contribute to immune evasion and therapeutic resistance. By combining cutting-edge single-cell multi-omics techniques and advanced 3D spatial transcriptomics, the study aims to elucidate the intricate molecular pathways responsible for diminished immune responses. The primary objective is to identify novel biomarkers and therapeutic targets that could enhance the development and precision of immunotherapies. Through this comprehensive analysis, the research will provide valuable insights into key signaling networks and cellular dynamics that shape immune responses, laying the groundwork for more effective and targeted treatment strategies in oncology.
To gather further insights into immune low-response states, we welcome articles focusing on, but not limited to, the following themes:
-Molecular pathways and signaling networks contributing to immune low-response states
-Application of single-cell technologies and spatial transcriptomics for immune system profiling
-Identification of novel biomarkers and therapeutic targets for improving immunotherapy
-Investigating the dynamic interactions between immune cells and other components within the immune system
-Integrating single-cell multi-omics with spatial transcriptomics to unravel immune cell heterogeneity
-Employing multi-omics strategies to explore mechanisms of immune evasion
-Development of targeted immunotherapies based on molecular interactions within the immune response
-Personalized and precision strategies to optimize immunotherapy and bolster immune responses
These focused efforts aim to advance our understanding of immune low-response states and drive innovations to improve patient outcomes, particularly in cancer treatment.
Immune low-response states significantly impact the effectiveness of immunotherapy in cancer treatment. These states typically arise from intricate molecular interactions between tumor cells and immune cells, which can suppress or alter the body's natural immune defense mechanisms. Recent breakthroughs in single-cell omics and spatial transcriptomics have equipped researchers with advanced tools to investigate these immune low-response environments with greater precision. Techniques such as ATAC-seq, TCR/BCR sequencing, RNA-seq, along with platforms like SLAT and STAligner, provide detailed insights into immune cell activity, gene expression profiles, and the dynamic nature of immune responses at the single-cell level. These technologies offer a deeper understanding of the mechanisms behind immunotherapy resistance and help clarify the role of immune cells in driving low-response states within cancer.
This Research Topic focuses on unraveling the molecular mechanisms that underpin immune low-response states, with an emphasis on the cellular and molecular interactions that contribute to immune evasion and therapeutic resistance. By combining cutting-edge single-cell multi-omics techniques and advanced 3D spatial transcriptomics, the study aims to elucidate the intricate molecular pathways responsible for diminished immune responses. The primary objective is to identify novel biomarkers and therapeutic targets that could enhance the development and precision of immunotherapies. Through this comprehensive analysis, the research will provide valuable insights into key signaling networks and cellular dynamics that shape immune responses, laying the groundwork for more effective and targeted treatment strategies in oncology.
To gather further insights into immune low-response states, we welcome articles focusing on, but not limited to, the following themes:
-Molecular pathways and signaling networks contributing to immune low-response states
-Application of single-cell technologies and spatial transcriptomics for immune system profiling
-Identification of novel biomarkers and therapeutic targets for improving immunotherapy
-Investigating the dynamic interactions between immune cells and other components within the immune system
-Integrating single-cell multi-omics with spatial transcriptomics to unravel immune cell heterogeneity
-Employing multi-omics strategies to explore mechanisms of immune evasion
-Development of targeted immunotherapies based on molecular interactions within the immune response
-Personalized and precision strategies to optimize immunotherapy and bolster immune responses
These focused efforts aim to advance our understanding of immune low-response states and drive innovations to improve patient outcomes, particularly in cancer treatment.